| DC65792 |
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
Featured
|
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin. |
|
| DC65793 |
1,2-Di(cis-13-docosenoyl)-sn-glycero-3-phosphoethanolamine |
|
|
| DC65794 |
O-LySoPC
Featured
|
|
|
| DC65795 |
2-Bromoisobutyric acid((s)-1，2-dimyristoyl-SN-giycerol)ester
Featured
|
|
|
| DC65796 |
Tritridecanoin Standard |
|
|
| DC65797 |
Diheptanoyllecithin |
Diheptanoyllecithin is a non-hydrolyzable analog. |
.gif)
|
| DC65798 |
DBr-1
Featured
|
DCAF1-BRD9 PROTAC DBr-1 potently degrades BRD9 with a DC50 of 90 nM but only weakly affected BRD7 protein levels. DBr-1 provides an alternative strategy to tackle intrinsic resistance to VHL-degrader. |
|
| DC65799 |
Compound 38 (NNMT inhibitor)
Featured
|
Compound 38 (NNMT inhibitor) is a potent uncompetitive inhibitors of nicotinamide n-methyltransferase (NNMT). Compound 38 inhibits NNMT in both in vitro biochemical and cell-based assays with IC50 = 42 nM and 38 nM, respectively. Compound 38 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. |
|
| DC65800 |
ARV-393
Featured
|
ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma. |
.gif)
|
| DC65801 |
ARV-102
Featured
|
a LRRK2 degrader for the treatment of PD and PSP |
|
| DC65802 |
KT-621 |
a STAT6 degrader for multiple immune-mediated diseases. |
|
| DC65803 |
KT-294
Featured
|
a TYK2 degrader for multiple immune-mediated diseases. |
|
| DC65804 |
HP518
Featured
|
an AR degrader for the treatment of mCRPC. |
|
| DC65805 |
BMS-986365 (CC-94676)
Featured
|
BMS-986365 (CC-94676) is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. BMS-986365 (CC-94676) is about 100-fold more potent than enzalutamide (ENZ) at inhibiting androgen-stimulated transcription of AR target genes, and 10 to 120-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro. |
|
| DC65806 |
AC682
Featured
|
an ER degrader for the treatment of BC. |
|
| DC65807 |
BGB-16673
Featured
|
a BTK degrader for the treatment of B-cell malignancies. |
|
| DC65808 |
HSK-29116
Featured
|
a BTK degrader for the treatment of B-cell malignancies. |
|
| DC65809 |
CG001419
Featured
|
a mutant and wild-type NTRK degrader for the treatment of solid tumors. |
|
| DC65810 |
KT-333
Featured
|
KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL). |
|
| DC65811 |
KT-253
Featured
|
a MDM2 degrader for the treatment of r/r high grade myeloid malignancies and solid tumors. |
|
| DC65812 |
ASP3082
Featured
|
a KRASG12D degrader for the treatment of solid tumors. |
|
| DC65813 |
FHD-609
Featured
|
a BRD9 degrader for treating synovial sarcoma. |
|
| DC65814 |
GT-20029
Featured
|
a topical AR degrader for the treatment of acne vulgaris. |
|
| DC65815 |
20-HETE inhibitor-1
Featured
|
20-HETE inhibitor-1 (comp 83) is a 20-HETE formation inhibitor |
|
| DC65816 |
APG-2575 (lisaftoclax)
Featured
|
APG-2575 (lisaftoclax) is a dual Bcl-2 and Bcl-xl inhibitor with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. |
|
| DC65817 |
Compound 4 (VHL-CDO1 glue degrader)
Featured
|
Compound 4 (VHL-CDO1 glue degrader) is a molecular glue degrader for cysteine dioxygenase 1 (CDO1) by recruiting it into the Von Hippel-Lindau (VHL) E3 ligase complex and leading to its selective degradation. |
|
| DC65818 |
CMX990
Featured
|
CMX990 is a novel covalent SARS-CoV-2 3CL protease inhibitor with EC50 of 10 nM, and shows good oral bioavailability and tolerability in preclinical species. Compared with nirmatrelvir, CMX990 has distinctly differentiated potency (~5-fold more potent in primary cells) and human in vitro clearance (>4-fold better microsomal clearance and >10-fold better hepatocyte clearance), with good in vitro-to-in vivo correlation. |
|
| DC65819 |
Acetylcholine
Featured
|
Acetylcholine is stored in vesicles in the presynaptic neuron. These fuse with presynaptic membrane upon stimulation by a nerve signal, thus, generating a pulse of neurotransmitter, which diffuses across the membrane. Acetylcholine may either bind reversibly to one of two different types of acetylcholine receptors on the postsynaptic membrane or be destroyed by the acetylcholine-hydrolyzing enzyme, acetylcholinesterase. |
|
| DC65820 |
Synucleozid-2.0
Featured
|
Synucleozid-2.0 is a drug-like small molecule that decreases α-Synuclein (SNCA) levels by inhibiting ribosomes from assembling onto SNCA mRNA. Synucleozid-2.0 dose-dependently inhibits SNCA translation with IC50 of ~2 µM. |
|
| DC65821 |
Upadacitinib hemihydrate
Featured
|
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders. |
|
